Cell injury inducing therapeutic drug for use in cancer therapy

A method for treating cancer, for inducing cytotoxicity, for suppressing cell proliferation, for inhibiting cell proliferation, or for activating immune response in an individual having cancer, comprising administering an effective amount of an antibody having CD3-binding activity, wherein the antibody comprises

• (a) H chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequences of the CDR1, CDR2, and CDR3 regions comprised in SEQ ID NO:
• 168, respectively;
• and
• (b) L chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequences of the CDR1, CDR2, and CDR3 regions comprised in SEQ ID NO:
• 223, respectively.

A method for treating cancer, for inducing cytotoxicity, for suppressing cell proliferation, for inhibiting cell proliferation, or for activating immune response in an individual having cancer, comprising administering an effective amount of an antibody having glypican 3-binding activity, wherein the antibody comprises

• (a) H chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequences of the CDR1, CDR2, and CDR3 regions comprised in SEQ ID NO:
• 206, respectively;
• and
• (b) L chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequences of the CDR1, CDR2, and CDR3 regions comprised in SEQ ID NO:
• 223, respectively.

A kit comprising:

• (A) a pharmaceutical composition comprising a bispecific antibody;
• (B) a container;
• and
• (C) an instruction or a label indicating that the bispecific antibody and at least one type of another anticancer agent are administered in combination to an individual for treating cancer in the individual,
• wherein the bispecific antibody comprises an antibody variable region having glypican 3-binding activity and an antibody variable region having CD3-binding activity,
• wherein the antibody variable region having glypican 3-binding activity and the antibody variable region having CD3-binding activity comprise a common L chain variable region, and
• wherein (a) the antibody variable region having glypican 3-binding activity comprises H chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequences of the CDR1, CDR2, and CDR3 regions comprised in SEQ ID NO:
• 206, respectively;
• (b) the antibody variable region having CD3-binding activity comprises H chain variable region CDR1, CDR2, and CDR3 comprising the amino acid sequences of the CDR1, CDR2, and CDR3 regions comprised in SEQ ID NO:
• 168, respectively;
• and (c) the common L chain variable region comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences of the CDR1, CDR2, and CDR3 regions comprised in SEQ ID NO:
• 223, respectively.